

Meet The Professor: Optimizing the Management of Gastroesophageal Cancers — Part 1 of a 5-Part Series

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. What was observed in the Phase III ORIENT-16 study comparing first-line sintilimab/chemotherapy to placebo/chemotherapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma?**
 - Improvement in overall survival with the sintilimab combination for all patients, regardless of PD-L1 combined positive score (CPS)
 - Improvement in overall survival with the sintilimab combination for only those patients with a PD-L1 CPS ≥ 5
 - Improvement in overall survival with the sintilimab combination for only those patients with a PD-L1 CPS ≥ 10
 - None of the above
- 2. What was observed regarding adjudicated drug-related interstitial lung disease (ILD)/pneumonitis rates in the DESTINY-Gastric02 study of trastuzumab deruxtecan for metastatic, HER2-positive gastric/GEJ cancers?**
 - ILD/pneumonitis was not observed
 - ILD/pneumonitis occurred in $<8\%$ of patients, the majority of which was Grade 1-2
 - ILD/pneumonitis occurred in 22% of patients, the majority of which was Grade 2-3
- 3. Which of the following resulted in the accelerated FDA approval of first-line pembrolizumab in combination with chemotherapy/trastuzumab for locally advanced unresectable or metastatic HER2-positive gastric GEJ adenocarcinoma?**
 - Improvement in overall survival
 - Improvement in progression-free survival
 - Improvement in overall response rate
- 4. Zolbetuximab is a novel monoclonal antibody directed against which cellular target?**
 - FGFR2-beta
 - Hepatocyte growth factor
 - Claudin 18.2
 - Mucin 17
 - Matrix metalloproteinase-9
- 5. Based on the pivotal CheckMate-577 study, nivolumab received approval as adjuvant therapy for patients in which of the following settings?**
 - Completely resected esophageal or GEJ cancer
 - Completely resected esophageal or GEJ cancer after neoadjuvant chemoradiotherapy
 - Completely resected esophageal or GEJ cancer after neoadjuvant chemoradiotherapy with residual pathologic disease
 - None of the above